ITER-like Wall

Learn More
The effects of ammonium chloride, methenamine hippurate and ascorbic acid on urinary pH was studied in 14 normal subjects. A statistically significant reduction of urinary pH was recorded with ammonium chloride in daily doses of 1.5 and 3 g, but not with 2 g of methenamine hippurate or 1.8 g of ascorbic acid. Long-term treatment with ammonium chloride in(More)
Based on the analysis of magnesium (Mg), ammonium (NH4), phosphate (P), urine pH, and urine volume (V), a simplified estimate (AP[MAP] index) of the ion-activity product of magnesium ammonium phosphate (AP MAP) was derived: (Formula: see text). The factor A varies according to the collection period. In 4-hour urine samples more than half of the patients(More)
Thirty-three patients operated on for renal staghorn calculous disease were studied retrospectively with respect to urine and stone composition, bacteriuria, and abnormalities of the urinary tract. Calcium phosphate was the most common stone constituent, present in 30 of 31 concrements. Twenty-one of these stones also contained magnesium ammonium phosphate,(More)
Experimental irrigation of 15 infectious renal stones with hemiacidrin resulted in complete dissolution of 11 stones within 5 days. Three of the undissolved stones had a calcium oxalate (CaOx) content of more than 10%. Stones containing calcium phosphate (CaP) and magnesium ammonium phosphate (MAP) and weighing less than 500 mg were most easily dissolved.(More)
The crystallization of magnesium ammonium phosphate (MAP) was studied in salt solutions and dialysed urine at similar levels of MAP supersaturation. At pH levels of 7.1 or higher crystallization occurred to the same extent in solutions with and without urinary macromolecules. Whereas crystals in the size range 3.5–5 μm were observed in the salt solution at(More)
Among 78 patients with hemiacidrin soluble staghorn renal stones, 23 were treated with a combination of one session of percutaneous debulking and high-energy extracorporeal shock wave lithotripsy (ESWL) (Group A); 17 were treated with high-energy ESWL only (Group B); and 38 were treated with low-energy only ESWL (Group C). In all patients percutaneous(More)
EUROfusion Consortium, JET, Culham Science Centre, Abingdon, OX14 3DB, UK 1 Department of Applied Physics, Ghent University, B-9000 Gent, Belgium 2 Institute of Plasma Physics and Laser Microfusion, Warsaw, Poland 3 Forschungszentrum Jülich GmbH, Institut für Klima-und Energieforschung-Plasmaphysik52425, Jülich, Germany 4 Max-Planck-Institut für(More)
  • 1